• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Anthera Pharmaceuticals, Inc. (ANTH)

    -NasdaqGM
    2.67 Down 0.34(11.30%) Feb 5, 4:00PM EST
    |After Hours : 2.67 0.00 (0.00%) Feb 5, 4:49PM EST
    ProfileGet Profile for:
    Anthera Pharmaceuticals, Inc.
    25801 Industrial Boulevard
    Suite B
    Hayward, CA 94545
    United States - Map
    Phone: 510-856-5600
    Fax: 510-856-5597
    Website: http://www.anthera.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:20

    Business Summary 

    Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Anthera Pharmaceuticals, Inc.

    Corporate Governance 
    Anthera Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Paul F. Truex MBA, 47
    Chief Exec. Officer and Director
    916.00K2.00K
    Ms. May Liu , 40
    Principal Accounting Officer, Compliance Officer and Sr. VP of Fin. & Admin.
    350.00K0.00
    Dr. Colin Hislop M.D., 58
    Chief Medical Officer and Sr. VP
    456.00K0.00
    Ms. Klara A. Dickinson-Eason , 48
    Chief Regulatory Officer and Sr. VP
    4.00KN/A
    Dr. Debra Odink Ph.D., 52
    Advisor
    448.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders